SenesTech 2025 Q3 Earnings 86.5% EPS Improvement Amid 43.2% Revenue Growth

SenesTech (SNES) reported mixed Q3 2025 results, with revenue growth outpacing estimates but missing top-line expectations. The net loss narrowed by 14.2%, while EPS improved by 86.5%, though the company remains unprofitable. Guidance emphasized operational efficiency and market expansion without specific financial targets.

Revenue

The company's total revenue for Q3 2025 reached $690,000, a 43.2% increase from the previous year, primarily driven by the Evolve Rodent Birth Control product line, which now constitutes 85% of total revenue. This segment growth was fueled by robust sales across e-commerce, municipal deployments, and pest management channels.

Earnings/Net Income

SenesTech narrowed its net loss to $1.30 million in Q3 2025, a 14.2% reduction from $1.51 million in the prior-year period. The loss per share improved to $0.28 from $2.07, a 86.5% improvement. Despite these gains, the company has reported losses for 10 consecutive years in this quarter, underscoring persistent financial challenges.

Price Action

The stock price of SenesTech declined 1.69% in the latest trading day but rose 5.78% over the past week. Month-to-date, it has fallen 15.74%, reflecting volatile investor sentiment.

Post-Earnings Price Action Review

The strategy of purchasing SenesTech shares on the date of its revenue raise announcement and holding for 30 days has historically yielded positive returns, with an average return of 12.5% per transaction, peaking at 20% and a minimum of 5% over the past three years. This suggests that the market has responded favorably to SenesTech's revenue milestones, although the stock has experienced a 15.74% decline month-to-date.

CEO Commentary

Joel Fruendt, CEO, highlighted the 77% year-over-year growth in Evolve Rodent Birth Control products, which now account for 85% of revenue. He emphasized a multi-channel distribution strategy and 62.8% gross margins, while noting a record Adjusted EBITDA loss of $1.2 million. Fruendt expressed optimism about the $10.2 million cash balance and the company’s path to breakeven.

Guidance

SenesTech anticipates accelerated e-commerce growth on platforms like Amazon and Walmart, expanded municipal deployments in cities like New York and Chicago, and retail expansion through partners like Ace Hardware. The company plans to leverage its cash reserves to scale the rodent fertility control market but provided no specific revenue or margin targets.

Additional News

1. Evolve Rat Birth Control Available on Lowes.com: SenesTech expanded its retail footprint by launching Evolve Rat Birth Control on Lowes.com, targeting homeowners and DIY consumers.

2. Corporate Relocation: The company relocated its headquarters and manufacturing operations to a larger facility in Surprise, Arizona, to boost production capacity.

3. 10-Q Report Highlights: The third-quarter 10-Q report noted a 33% revenue increase from Evolve products, 64.2% gross margin, and a 7% reduction in operational losses.

Key Takeaway: SenesTech’s Q3 results reflect progress in core product growth and cost management, but profitability remains elusive. Investors should monitor execution on multi-channel expansion and cash flow sustainability.